1,600 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Purchased by Everence Capital Management Inc.

Everence Capital Management Inc. purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,600 shares of the medical research company’s stock, valued at approximately $378,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Charles River Laboratories International by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,953,860 shares of the medical research company’s stock worth $1,166,837,000 after buying an additional 29,482 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Charles River Laboratories International by 35.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company’s stock worth $505,821,000 after buying an additional 653,790 shares during the period. State Street Corp increased its stake in Charles River Laboratories International by 1.8% in the 2nd quarter. State Street Corp now owns 2,091,017 shares of the medical research company’s stock worth $439,636,000 after buying an additional 37,816 shares during the period. Kayne Anderson Rudnick Investment Management LLC increased its stake in Charles River Laboratories International by 3.9% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,746,101 shares of the medical research company’s stock worth $342,201,000 after buying an additional 64,981 shares during the period. Finally, Moneta Group Investment Advisors LLC purchased a new position in Charles River Laboratories International during the 4th quarter valued at about $298,877,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of research reports. Robert W. Baird raised their target price on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a research report on Thursday, February 15th. Evercore ISI raised their target price on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a research report on Thursday, February 15th. UBS Group raised their target price on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. Finally, Guggenheim downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.23.

Charles River Laboratories International Stock Down 1.1 %

CRL stock opened at $227.55 on Friday. The firm has a 50 day moving average of $253.64 and a 200 day moving average of $220.96. The stock has a market capitalization of $11.72 billion, a PE ratio of 24.71, a price-to-earnings-growth ratio of 1.82 and a beta of 1.40. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. Charles River Laboratories International’s revenue for the quarter was down 7.9% on a year-over-year basis. During the same period last year, the business earned $2.98 EPS. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Victoria L. Creamer sold 5,000 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Victoria L. Creamer sold 5,000 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the sale, the vice president now directly owns 22,879 shares in the company, valued at $5,685,431.50. The disclosure for this sale can be found here. Insiders sold 14,932 shares of company stock worth $3,693,663 in the last three months. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).